Skip Navigation
Skip to contents

대한신장학회


간행물 검색

현재 페이지 경로
  • HOME
  • 간행물
  • 간행물 검색
논문분류 춘계학술대회 초록집
제목 Efficacy and Safety of Metformin in the Patients with Type 2 Diabetic Chronic Kidney Disease
저자 Soie Kwon1, Yong Chul Kim1, Jae Yoon Park3, Jeong Hwan Lee2, Young Lee Jung2, Jung Nam An2, Dong Ki Kim1, Chun Soo Lim2, Jung Pyo Lee2
출판정보 2018; 2018(1):
키워드 Metformin | Chronic kidney disease | Diabetes mellitus | mortality | Lactic acidosis
초록 Objectives: Metformin is widely used as the best pharmacological option in the patients with type 2 diabetes mellitus. However, use of this drug has not been recommend in individuals with impaired kidney function because of the perceived risk of lactic acidosis. We aimed to assess the efficacy and safety of metformin in patients with type 2 diabetic chronic kidney disease (CKD). Methods: We conducted a retrospective, observational, cohort study of 11,678 patients with type 2 diabetic CKD who followed the nephrology clinic at two tertiary hospitals from 2001 to 2016. We compared 3768 patients who used metformin with 7910 who did not use metformin. Primary outcome was defined as all-cause mortality. Secondary outcomes were kidney function, end-stage renal disease (ESRD) progression and event of lactic acidosis. Results: The patients who used metformin had more female proportion, lower eGFR, and higher HbA1c level at the time of enrollment. Metformin-used group was better able to preserve kidney function. The all-cause mortality for metformin-used group was significantly better than that for non-metformin user in the multivariable cox analysis (P value <0.001 adjusted hazard ratio [aHR] 0.53, 95% confidence interval [C.I.] 0.45 - 0.62). Also, MFM group has longer duration of ESRD progression. (P value = 0.002, aHR 0.78, 95% CI 0.67 – 0.92). Also, there was no lactic acidosis event in both groups. Conclusions: In Korean diabetic CKD patients, metformin could be safely used. However, more researches about how to use such as dose and monitoring are needed.
원문(PDF) PDF 원문보기
위로가기